Business Context and Reporting Period
This is Galena Biopharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012; the filing does not identify SELLAS Life Sciences Group, Inc. as the registrant. Galena was a development-stage biopharmaceutical company with no revenue. Its lead candidate, NeuVax, was in Phase 3 and Phase 2 trials; its Folate Binding Protein vaccine was in Phase 1. Galena completed the spin-off of its RNAi-focused subsidiary, RXi, on April 27, 2012.
Financial Results and Liquidity
Amounts below are in millions of dollars, except per-share data. Revenue and gross margin are not applicable because Galena had no revenue.
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Research and development expense | $3.671 | $2.156 |
| General and administrative expense | $1.939 | $3.119 |
| Operating loss | $(5.610) | $(5.275) |
| Other income (expense) | $(19.114) | $1.435 |
| Net loss | $(24.761) | $(3.841) |
| Basic and diluted loss per share | $(0.52) | $(0.19) |
| Cash used in operating activities | $(4.885) | $(3.027) |
| Cash and cash equivalents at period end | $8.701 | $11.115 |
At March 31, 2012, total assets were $28.208 million, total liabilities $38.778 million, and stockholders’ deficit $10.570 million. Current liabilities were $27.392 million, including $20.357 million of warrants potentially settleable in cash. Convertible notes payable totaled $1.0 million; capital lease obligations totaled $0.060 million. The balance sheet also included $6.195 million of contingent purchase-price consideration, of which $0.898 million was current.
Changes Versus Prior Comparable Period
- Net loss increased $20.920 million, or approximately 545%. The main driver was a $19.705 million increase in expense related to warrants accounted for as liabilities and settled during the quarter, plus an $0.844 million increase in fair-value expense for contingent purchase consideration.
- Research and development expense rose 70%, mainly from the Phase 3 PRESENT trial ramp-up. General and administrative expense declined 38%, primarily due to lower non-cash employee stock compensation and personnel and professional-service costs.
- Operating cash use increased by $1.858 million. Cash and cash equivalents fell $2.732 million from year-end 2011.
Outlook, Risks, Contingencies, and Unusual Items
- Management expected significant operating losses and increased R&D spending, with no product revenue expected in the foreseeable future. Galena estimated that cash and cash equivalents would fund operations through at least the second quarter of 2013, while warning that further financing might be needed and might not be available on acceptable terms or at all.
- After quarter-end, Galena reported approximately $24.9 million in cash and cash equivalents at April 30, 2012, reflecting about $13.3 million in net proceeds from an April offering and about $4.1 million from warrant exercises.
- The April offering issued 8.5 million shares at $1.50 per share; underwriters exercised an option for an additional 1.251 million shares. Subsequent warrant exercises also issued 6.363 million shares for approximately $4.136 million.
- The large quarterly loss was substantially affected by non-cash warrant remeasurement expense; warrant liabilities increased sharply, and their fair value is sensitive to valuation inputs. Potential dilution was material: 13.117 million warrants and 7.438 million options were outstanding at March 31, excluding other share reservations.
- Apthera acquisition consideration included up to $32 million of future milestone payments. A $1 million milestone was triggered by the first patient enrolled in the NeuVax Phase 3 trial; payment was subject to shareholder approval, with interest also accruing.
- Warrant-holder litigation over claimed repurchase rights remained a contingency. Plaintiffs withdrew most demands; Galena tendered $355,000 for the remaining 500,000 underlying shares, and one plaintiff entered a confidential settlement on May 7, 2012. The filing does not establish that all claims were resolved.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. The filing refers investors to the 2011 Form 10-K for risk factors.
Investor Verification Priorities
- Confirm the registrant: this filing is for Galena Biopharma, Inc., not SELLAS Life Sciences Group, Inc.
- Check post-quarter financing, warrant exercises, share issuance, and resulting dilution against subsequent filings.
- Assess the cash runway and operating cash burn relative to management’s stated funding horizon and expected clinical-trial costs.
- Review warrant liability valuation and the potential cash, earnings, and dilution consequences of warrant terms.
- Verify the status and ultimate cost of Apthera milestone obligations and the remaining warrant-holder litigation.
- Track clinical progress and financing needs for NeuVax and the other development programs; no product revenue or profitability guidance was provided.